Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report

Lucas Souto Nacif1*, Daniel R. Waisberg1, Rafael Soares Pinheiro1, Fabiana Roberto Lima2, Vinicius Rocha-Santos1, Wellington Andraus1 and Luiz Carneiro D’Albuquerque1

Abstract

Background: There is a worldwide problem of acute liver failure and mortality associated with remaining on the waiting for a liver transplant. In this study, we highlight results published in recent years by leading transplant centers in evaluating imatinib-induced acute liver failure in chronic myeloid leukemia and follow-up in liver transplantation.

Case presentation: A 36-year-old brown-skinned woman (mixed Brazilian race) diagnosed 1 year earlier with chronic myeloid leukemia was started after delivery of a baby and continued for 6 months with imatinib mesylate (selective inhibitor of Bcr-Abl tyrosine kinase), which induced liver failure. We conducted a literature review using the PubMed database for articles published through September 2017, and we demonstrate a role of liver transplant in this situation for imatinib-induced liver failure. We report previously published results and a successful liver transplant after acute liver failure due to imatinib-induced chronic myeloid leukemia treatment.

Conclusions: We report a case of a successful liver transplant after acute liver failure resulting from imatinib-induced chronic myeloid leukemia treatment. The literature reveals the importance of prompt acute liver failure diagnosis and treatment with liver transplant in selected cases.

Keywords: Acute liver failure, Liver transplantation, Organ graft, Transplantation

Background

Liver transplant (LT) is an excellent therapeutic option for acute liver failure (ALF) [1]. Rapid clinical manifestation and severe hepatic injury can arise from many drugs used to treat ALF [1]. However, some situations are very unusual in clinical practice and can be related to oncological blood diseases, including chronic myeloid leukemia (CML).

Imatinib-induced ALF in a patient with CML was first described as being managed with dasatinib [2]. Even though severe hepatotoxicity may be observed in 1–4% of patients treated with imatinib, cases of fulminant liver failure are rare, with only eight known cases [2–9]. All cases but one involved patients with CML, and most of the cases were fatal [3–7]. LT was reported in four of them [2, 5, 8, 9], with one postoperative death [5]. Nilotinib was used after LT in two cases [8, 9], and Harding et al. first described dasatinib therapy [2]. In this report, we review the literature and report another successful case of LT for imatinib-induced liver failure.

Case presentation

A 36-year-old brown-skinned woman (mixed Brazilian race) was admitted to our institution with jaundice, nausea, mild right upper abdominal pain, choluria, and acholia of 1 week’s duration. She had been diagnosed with CML 1 year before (during her 22nd week of pregnancy). Treatment with standard dose (400 mg/day) imatinib (Gleevec; Novartis, Basel, Switzerland) had been started after
delivery and was continued for 6 months, with no adverse
effects until 45 days prior to admission, when a mild eleva-
tion in liver enzymes was observed (aspartate transaminase
[AST] 229 IU/L, alanine transaminase [ALT] 111 IU/L).

Imatinib was discontinued, but the patient presented
on admission with ALT 1422 IU/L, AST 1690 IU/L, total
bilirubin 13.08 mg/dl, prothrombin time > 50 (inter-
national normalized ratio 2.38), fibrinogen < 50 mg/dl,
and factor V Leiden 11%. An abdominal ultrasound re-
vealed no abnormalities. The results of viral screening
were negative for hepatitis B (hepatitis B surface antigen,
anti-hepatitis B core antibody), hepatitis C (anti-hepatitis
C virus), human immunodeficiency virus (anti-HIV-1/II),
cytomegalovirus (immunoglobulin G [IgG]-positive and
IgM-negative), and Epstein-Barr virus. The results were
also negative for autoimmune hepatitis (antimitochon-
drial antibody, anti-LKM1 antibody to liver kidney
microsome type 1, and antinuclear antibody). The pa-
tient’s copper serum levels were normal (39 μg/dl). The
laboratory findings associated with hyperammonemia
and clinical manifestation of grade II/III encephalopathy
led to the diagnosis of ALF.

The patient met the King’s College (O’Grady) and
Clichy criteria and then underwent urgent orthotopic LT
the next day. The graft weighed 0.930 kg. Total ischemic
time and warm ischemic time were 6.9 hours and 35 mi-
utes, respectively. The donor was a 40-year-old woman
with brain death resulting from a ruptured brain
aneurysm. The donor presented the following extended
criteria: vasoactive drug use (noradrenalin 0.05
μg/kg/minute and vasopressin 0.1 μg/kg/minute), infection
(nosocomial pneumonia, use of piperacillin/tazobactam
for 3 days), and long intensive care unit stay (17 days).
The postoperative transaminase peaks were ALT and
AST of 668 IU/L and 760 IU/L, respectively. The im-
munosuppressive regimen featured steroids (STs) and
calcineurin inhibitors as well as tacrolimus (Libbs, São
Paulo, Brazil). This regimen was administered as a ST
bolus during the anhepatic phase (methylprednisolone
500 mg) and was decreased to 20 mg/day and tapered to
a complete stop within 6 months of LT. Tacrolimus was
orally administered and maintained (0.10–0.15 mg/kg/
day administered orally twice per day every 12 hours).

The patient had a good evolution during the postoper-
ative period and was tracheally extubated on the second
day. However, on the fourth postoperative day, she
underwent a laparotomy day because of hemodynamic
instability, coagulopathy, increased drainage through ab-
dominal drains, and serum hemoglobin decrease after
hemotransfusion without major bleeding. On the sixth
postoperative day, the patient presented acute dyspnea
and pulmonary congestion. Further investigation with
pulmonary angiographic computed tomography ruled
out pulmonary embolism. An echocardiogram showed
an ejection fraction of 35% (previously 65%) without is-
chemic cardiac or coronary abnormalities. These symp-
toms were attributed to myocardiopathy secondary to
systemic inflammatory response syndrome (SIRS). We
excluded all other causes of cardiomyopathy (vascular,
muscular, or infectious involvement, including sepsis).
The patient presented a satisfactory evolution with low
doses of diuretics and beta-blockers (carvedilol). She was
discharged on the 25th postoperative day.

The histopathological report revealed severe acute hepa-
titis (Fig. 1a–d) with submassive hepatic necrosis, which is
compatible with the patient’s subacute hepatic failure.
Upon gross examination, the liver weighed 436 g, and the
Glisson’s capsule was focally wrinkled. Histological ex-
amination showed that the more preserved parenchyma had
a green to tan appearance in contrast to some irregular
reddish-brown zones representing extensive necrotic areas.
The left lobe was more severely damaged than the right.

Microscopically, areas of panacinar and multifocal
necrosis were intermingled with large areas of less affected
parenchyma exhibiting confluent and bridging necrosis.
The inflammatory infiltrate in portal tracts varied in in-
tensity, usually with a predominance of mononuclear
cells. Other findings included remarkable ductular reac-
tion, collapsed reticulin framework, significant cholesta-
sis, mild steatosis, hepatic enzyme induction, acidophilic
bodies, and regeneration of hepatocytes. Plasma cells
were not prominent. Neither granuloma formation nor
eosinophil-rich infiltrate was detected. No components
or any evidence of CML was found in the liver explant.

The patient remained asymptomatic for CML; never-
theless, her BCR-ABL transcript rose to 148% 4 months
after LT. It was 0.41% prior to imatinib withdrawal.
Dasatinib (Bristol-Myers Squibb, New York, NY, USA)
was then introduced at 60 mg/day because of the pa-
tient’s prior history of myocardiopathy related to SIRS.
The patient’s BCR-ABL transcript reduced to 10.64% after 2 months.

At follow-up, the patient’s liver function laboratory
tests (total bilirubin, transaminase levels, and coagula-
tion profile), as well as her vascular and biliary tract
(ultrasound and magnetic resonance imaging), remained
normal 10 months after the LT. The patient returned to
her daily routine.

Ethical aspects
This study was approved by the institutional review
board of our institution and fulfilled all of the require-
ments for studies in humans. It adhered to the guide-
lines of the 1975 Declaration of Helsinki.

Discussion
Imatinib mesylate is a selective inhibitor of Bcr-Abl tyro-
sine kinase and is the first-line treatment for patients
with CML without a suitable bone marrow donor or in whom transplant would be inadvisable [3]. It is also used for the systemic treatment of advanced gastrointestinal stromal tumors (GISTs) [10]. Hepatic toxicity is usually resolved with either dosage reduction or discontinuation of imatinib [3], which has been permanently required in 0.5% of patients [6]. In this scenario, second-generation tyrosine kinase inhibitors such as dasatinib, nilotinib, sunitinib, and regorafenib may be used [2, 8, 9, 11, 12].

Imatinib-related severe acute hepatitis has been described in 11 cases with favorable outcome after drug interruption (all cases) and use of prednisolone (four cases) [10]. Nine patients were female, two were male, and their age ranged from 22 to 64 years. Nine cases were CML and two were GISTs. It is interesting to note that the time between imatinib start and hepatotoxicity varied from less than 2 weeks to 77 weeks in these cases.

Table 1 presents nine cases of imatinib-related fulminant liver failure found in the literature. No ST treatment was attempted in any of these cases. The time between imatinib start and hepatotoxicity varied from 6 days to 77 weeks; nonetheless, all but two cases had at least 20 weeks of imatinib use. LT was performed in five cases.

The pathogenesis of hepatotoxicity due to imatinib is unclear and may be related to hazards of drug association. Cytochrome P450 enzymes such as CYP3A4, CYP2C9, and CYP2D6 are responsible for imatinib metabolism [5, 10]. Inhibitors of CYP3A4, such as

| Author [reference] | Year | Patient age and sex | Diagnosis | Time between imatinib start and hepatotoxicity | Treatment | Outcome |
|--------------------|------|----------------------|-----------|-----------------------------------------------|-----------|---------|
| Talpaz et al. [3]  | 2002 | Not reported         | CML       | 6 days                                        | Drug interruption | Death   |
| Lin et al. [4]    | 2003 | 61 years, female     | PV        | 7 weeks                                       | Drug interruption | Death   |
| Cross et al. [5]  | 2006 | 46 years, female     | CML       | 77 weeks                                      | LT         | Death   |
| Ridruejo et al. [6]| 2007 | 51 years, female     | CML       | 20 weeks                                      | Drug interruption | Death   |
| Thia et al. [7]   | 2008 | 45 years, female     | CML + chronic hepatitis B | 20 weeks                                      | Drug interruption | Death   |
| Perini et al. [8] | 2009 | 47 years, female     | CML       | 72 weeks                                      | LT         | Survived|
| Martinez Pascual et al. [9]| 2010 | 34 years, female     | CML       | 32 weeks                                      | LT         | Survived|
| Harding et al. [2] | 2016 | 30 years, female     | CML       | 20 weeks                                      | LT         | Survived|
| Present case      | 2017 | 36 years, female     | CML       | 30 weeks                                      | LT         | Survived|

Abbreviations: CML chronic myeloid leukemia, PV Polycythemia vera, LT Liver transplant.
erythromycin, clarithromycin, itraconazole, roxithromycin, levonorgestrel, ethinylestradiol, cyproterone (present in some oral contraceptives), and grapefruit juice, increase imatinib concentration and can result in toxicity. In two cases of severe acute hepatitis, patients were receiving acetaminophen as well [10]. Duloxetine is metabolized by CYP1A2 and CYP2D6 pathways. These were present in one patient who ultimately underwent LT [8]. Therefore, caution should be taken when administering other hepatotoxic drugs.

Even though nilotinib and dasatinib are structurally similar to imatinib and are metabolized by the CYP3A4 pathway, previous reports have confirmed a lack of cross-intolerance. Its use appears to be safe even in cases of severe toxicity associated with imatinib. However, sunitinib and regorafenib have been associated with fatal fulminant liver failure [11] and severe acute hepatitis [12], respectively. In both cases, patients had advanced GISTs that were unresponsive to imatinib. Interestingly, no previous hepatotoxicity had been observed with this association.

Although rare, ALF in patients with oncological diseases results in ethical dilemmas. There is a scarcity of liver grafts and high mortality of patients on a waitlist. Transplant patients who may have limited survival owing to tumor recurrence might not be the best candidates. They can also suffer more than most from immunosuppression. On the other hand, fulminant liver failure is an emergency that leads to death within a few days unless the patient undergoes LT. Therefore, is it justified to abruptly shorten oncological patients’ survival if they have a favorable prognosis? There is no definitive answer. Thus, the decision must be individualized to each patient and deeply discussed by the LT recipient and the oncology teams.

Conclusions
Imatinib-related CML cases are candidates for LT, given the favorable outcome of the few cases reported in the literature and the possibility of using equally effective medications during the post-transplant period.

Abbreviations
ALF: Acute liver failure; ALT: Alanine transaminase; AST: Aspartate transaminase; CML: Chronic myeloid leukemia; CYP: Cytochrome P450 enzyme; GIST: Gastrointestinal stromal tumor; Ig: Immunoglobulin; LT: Liver transplant; PV: Polycythemia vera; SIRS: Systemic inflammatory response syndrome; ST: Steroid

Acknowledgements
Not applicable.

Funding
Not applicable.

Availability of data and materials
All data presented in this manuscript are provided with in-text citations with corresponding references provided in the References section. No datasets were generated or analyzed during this study.

Authors’ contributions
DRW and LSN conceived of and designed the study; collected, analyzed, and interpreted data; and wrote the manuscript. RSP conceived of and designed the study; collected, analyzed, and interpreted data; and critically revised the manuscript. FRL and VRS collected, analyzed, and interpreted data and critically revised the manuscript. WA and UCD conceived of the study, interpreted data, and critically revised the manuscript. All authors approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests. No writing assistance was used in the production of this manuscript.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1. Liver and Gastrointestinal Transplant Division, Department of Gastroenterology, University of São Paulo School of Medicine, Rua Dr. Enéas de Carvalho Aguiar, 255-90 andar-sala 9113/9114, São Paulo, SP, CEP05404-900, Brazil. 2. Department of Pathology, University of São Paulo School of Medicine, São Paulo, Brazil.

Received: 8 December 2017 Accepted: 27 January 2018

Published online: 10 March 2018

References
1. Hessheimer AJ, Nacif L, Flores Villalta E, Fondevila C. Liver transplantation for acute liver failure. Cir Esp. 2017;95(4):181–9.
2. Harding DJ, MacQuillan G, Howman R, de Boer B, Adams L, Mitchell A, Jeffrey G. Successful use of dasatinib after liver transplantation for imatinib-induced fulminant liver failure in chronic myeloid leukemia. J Clin Oncol. 2016;34(11):e97–8.
3. Taltaz M, Silver R, Druker B, Goldman J, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928–37.
4. Lin N, Sarampoulos S, Stone J, Gallinsky L, Stone R, Deangelo D, et al. Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003;102:3455–6.
5. Cross T, Bagot C, Portmann WJ, Gillot D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol. 2006;81:189–92.
6. Riduque E, Cacchione R, Villanil AG, Marciano S, Gadano AC, Mando OG. Imatinib-induced fatal hepatic failure. World J Gastroenterol. 2007;13:6608–11.
7. Thua TJ, Tan HH, Chuah TH, Chow WC, Lui HF. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukemia and chronic hepatitis B infection. Singap Med J. 2008;49:886–9.
8. Perini G, Santos F, Funke V, Ruiz J, Ferraz B, Hamerschlag N. Nilotinib post-liver transplantation for acute hepatocellular failure related to imatinib. Leuk Res. 2009;33:234–5.
9. Martinez Pascual C, Valdés Mas M, de la Peña Moral JM, Miras López M. Fulminating hepatitis for imatinib in a patient with chronic myeloid leukemia [in Spanish]. Med Clin (Barc). 2011;137(7):329–30.
10. Tontani O, Coskun U, Yildiz R, Karakan T, Demirci U, Akyurek N, Benekli M, Buyukberber S. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Med Oncol. 2010;27(3):768–73.
11. Weise AM, Liu CY, Shields AF. Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levetiracetame. Ann Pharmacother. 2009;43(4):761–6.
12. Akamine T, Ando K, Oki E, Sarks H, Nakashima Y, Imaizumi Y, Ohgaki K, Maehara Y. Acute liver failure due to regorafenib may be caused by impaired liver blood flow: a case report. Anticancer Res. 2015;35(7):4037–41.